Traders should monitor upcoming trial initiations and enrollment timelines for the Phase 2 studies in DMD and ALS, as these will be key catalysts. The positive biomarker and safety data reduce near-term clinical risk, potentially supporting valuation upside ahead of clinical milestones.
KROS drugs
KROS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $11.35entry
- T+1 · 8mo ago +2.03%α +2.21% · $11.58
- T+5 · 8mo ago −2.82%α −1.46% · $11.03
- T+20 · 7mo ago +7.84%α +10.65% · $12.24
- T+60 · 6mo ago −7.05%α −19.04% · $10.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target engagement, favorable changes in muscle and bone mass, and a good safety profile in healthy volunteers. The data support advancing rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), representing a meaningful step in the clinical development of the drug.
Key Facts
- Keros presented additional Phase 1 data for rinvatercept in healthy volunteers, confirming target engagement and mechanism of action.
- Rinvatercept was well-tolerated with no serious adverse events or dose-limiting toxicities.
- Treatment led to increased muscle mass, decreased fat mass, and improved bone mineral density.
- Proteomic data showed anti-fibrotic and anti-inflammatory effects, aligning with preclinical findings.
- Company plans to advance rinvatercept into Phase 2 trials for DMD and ALS.
Financial Impact
No direct financial impact reported; potential long-term value creation if Phase 2 trials succeed.
Risk Factors
- Phase 2 trials may not replicate Phase 1 results in patient populations.
- Clinical development timelines could be delayed due to enrollment, regulatory, or manufacturing challenges.
- Competition exists in both DMD and ALS spaces with other biotech firms developing novel therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251751 |
Track record
27 reports on KROS
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers